BTA 9881

Drug Profile

BTA 9881

Alternative Names: AZD9639; BTA9881; MEDI-564

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biota Holdings
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 31 Aug 2009 BTA 9881 is no longer licensed to MedImmune/AstraZeneca
  • 16 Jul 2007 Phase-I clinical trials in Respiratory syncytial virus infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top